Journal of Modern OncologyJournal of Modern OncologyСовременная онкология1815-14341815-1442LLC Obyedinennaya Redaktsiya26566ArticlesСтатьиResearch ArticleFaktory prognoza pri rake molochnoy zhelezyФакторы прогноза при раке молочной железыBozhokA AБожокА АSemiglazovV FСемиглазовВ ФSemiglazovV VСемиглазовВ ВArzumanovA SАрзумановА СKletsel'A EКлетсельА ЕГУН НИИ онкологии им. проф. Н.Н.Петрова, Санкт-ПетербургСанкт-Петербургский государственный медицинский университет им. акад. И.П.ПавловаЦентральный научно-исследовательский рентгенорадиологический институт, Санкт-ПетербургКлиника онкологии и гинекологии, Оснабрюк, Германия1503200571VOL 7, NO1 (2005)ТОМ 7, №1 (2005)4909042020Copyright ©; 2005, Consilium MedicumCopyright ©; 2005, ООО "Консилиум Медикум"2005Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc/4.0https://modernonco.orscience.ru/1815-1434/article/view/26566

Основная задача адъювантного лечения при раке молочной железы (РМЖ) - максимальный эффект при минимальных токсических воздействиях. Она разрешима только путем индивидуализации терапии, т.е. с учетом факторов, предсказывающих эффект от лечения и прогноз течения заболевания. До сих пор выбор адъювантного лечения основывался на учете степени местно-регионарного распространения опухоли (система TNM), уровня экспрессии рецепторов к стероидным гормонам и репродуктивном статусе (или, чаще, возрасте) больных. Как показывают результаты клинических исследований, этой информации недостаточно для планирования адекватного лечения. Настоящая статья посвящена обзору имеющейся информации о значении различных молекулярных маркеров для определения прогноза и выбора терапии при РМЖ.

рак молочной железыметод лечениявыбормаркерыпрогнозадъювантная терапиягеномрецидиврискАрзуманов А.С. Современная лучевая диагностика и комплексное лечение больных раком молочной железы с высоким риском прогрессирования. Спб., 2002.Моисеенко В.М., Семиглазов В.Ф., Тюляндин С.А. Современное лекарственное лечение местно - распространенного и метастатического рака молочной железы. Спб.: Грифон, 1997.Семиглазов В.Ф., Веснин А.Г., Моисеенко В.М. Минимальный рак молочной железы. Спб., 1992.Семиглазов В.Ф., Нургазиев К.Ш., Арзуманов А.С. Опухоли молочной железы (лечение и профилактика). Алматы, 2001.Семиглазов В.Ф., Арзуманов А.С., Божок А.А. и др. Новый взгляд на неоадъювантную химиотерапию рака молочной железы (роль навельбина). Совр. онкол. 2003; 5 (3): 103-7.Семиглазов В.В. Клиническая характеристика и лечение неинвазивных и минимальных инвазивных форм рака молочной железы. Спб.: Эскулап, 2004.Aas T, Geisler S, Eide G.E et al. Predictive value of tumor cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2003; 39 (4): 438-46.Allred D.C, Clark G.M, Tandon A.K et al. Her-2neu in node - negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599-605.Amat S, Penault-Llorca F, Cure H et al. Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 2002; 20 (4): 791-6.Anelli A, Brentani R.R, Gadelha A.P et al. Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer. Ann Oncol 2003; 14 (7): 1156.Bonetti A, Zaninelli M, Leone R et al. bcl-2 but not p-53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 1998; 4: 2331-6.Bonnefoi H, Diebold-Berger S, Therasse P et al. Locally - advanced\inflammatory breast cancers treated with intensive epirubicin - based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol 2003; 14 (3): 406-13.Bottini A, Berruti A, Bersiga A et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 2000; 6: 2751-8.Bottini A, Berruti A, Brizzi M.P et al. Single agent epirubicin versus the combination epirubicin plus tamoxifen as primary chemotherapy in breast cancer patients. A single institution phase III trial. Proc Am Soc Clin Oncol 2003; 22: abstract 80.Buchholtz T.A, Davis D.W, Mc Concey D.J et al. Chemotherapy - induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer 2003; 9: 33-41.Buzdar A.U, Valero V, Theriault R.L et al. Pathological complete4 response to chemotherapy is related to hormone receptor status. Proc Breast Cancer Conf., San Antonio. 2003; abstract 302.Campiglio M, Somenzi G, Ogliati C et al. Role of proliferation in Her2 status predicted response to doxorubicin. Int J Cancer 2003; 105 (4): 568-73.Chang J.C.N, Wooten E.C, Tsimelzon A et al. Gene expression patterns for de novo and acquired docetaxel resistance in patients with locally advanced breast cancer. Proc Am Soc Oncol 2003; 22: 9 (abstr. 32).Chollet P, Amat S, Cure H et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002; 86 (7): 1041-6.Clark G.M, Dressler L.G, Owens M.A et al. Prediction of relapse or survival in patients with node - negative breast cancer by DNA flow cytometry. N Engl J Med 1989; 320: 627-33.Clark G.M, Allred D.C, Hilsenbeck S.G et al. Mitosin (a new proliferation marker) correlates with clinical outcome in node - negative breast cancer. Cancer Res 1997; 57: 5505-8.Coon J.S, Marcus E, Gupta-Burt S et al. Amplification and overexpression of topoisomerase II_ predict response to anthracicline - based therapy in locally advanced breast cancer. Clin Cancer Res 2002; 8: 1061-7.Crowe Jr.J.P, Gordon N.H, Hubay C.A et al. Estrogen receptor determination and long term survival of patients with carcinoma of the breast. Surg Gynecol Obstet 1991; 173: 273-8.De Placido S, De Laurentiis M, Carlomagno C et al. Twenty - year results of the Naples GUN randomized trial: Predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003; 9: 1039-46.de Witte J.H, Sweep C.G, Klijn J.G et al. Prognostic impact of urokinase - type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. Br J Cancer 1999; 79: 1190-8.Degeorges A, de Roquancourt A, Extra J.M et al. Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer? Breast Cancer Res Treat 1998; 47: 47-55.Del Mastro L, Bruzzi P, Venturini M et al. Her2 expression and efficacy of dose - dense anthracycline - containing adjuvant chemotherapy (CT) in early breast cancer (BC) patients. Proc Am Soc Clin Oncol 2004; 23 (abstr. 571).Di Leo A, Chan S, Paesmans M et al. Her-2neu as a predictive marker in a population of advanced breast cancer patients randomly treated either single - agent Doxorubicin or single - agent Docetaxel. Breast Cancer Res Treat 2004; 86 (3): 197-206.Eirmann W, Gianni L, Semiglazov V et al. European cooperative trial in operable breast cancer (ECTO) Proc Am Soc Clin Oncol 2003; 22: (abstr. 37).Elledge R.M, Green S, Ciocca D et al. Her-2 expression and response to tamoxifen in estrogen receptor - positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 1998; 4: 7-12.Ellis M, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-positive breast cancer. J Clin Oncol 2001; 19: 3808-16.Esteva F.J, Pusztai L, Symmans W.F et al. Clinical relevance of Her-2 amplification and overexpression in human cancers. Ref Gynecol Obstet 2000; 7: 267-76.Estevez L.G, Cuevas J.M, Anton A et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer. Clin Cancer Res 2003; 9: 686-92.Faneyte J.F, Schrama J.G, Peterse J.L et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003; 10 88 (3): 406-12.Gonzales-Angulo A.M, Krishnamurthy S, Yamamura Y et al. Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 2004; 101 (2): 258-63.Grondahi-Hansen J, Hilsenbeck S.G, Christensen I.J et al. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node - positive breast cancer patients. Breast Cancer Res Treat 1997; 43: 153-63.Harbeck N, Meisner C, Prechtl A et al. Level-1 evidence for prognostic and predictive impact of uPA and PAI-1 in node - negative breast cancer patients provided by second scheduled analysis of multicenter Chemo-N-0 therapy trial. Breast Cancer Res Treat 2001; 89: (abstract 213).Holmes F.A, Fritsche H.A, Loewy J.W et al. Measurement of estrogen and progesterone receptors in human breast tumors: enzyme immunoassay versus binding assay. J Clin Oncol 1990; 8: 1025-35.Ikeda T, Jinno H, Kitajima M et al. chemo sensivity - related genes of breast cancer detected by DNA microarray. Proc Am Soc Oncol 2003; 22: 9 (abstr. 34).Janicke F, Schmitt M, Pache L et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node - negative breast cancer. Breast Cancer Res Treat 1993; 24: 195-208.Janicke F, Prechtl A, Thomssen C et al. Randomized adjuvant chemotherapy trial in high - risk, lymph node - negative breast cancer patients identified by urokinase - type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-20.Jarvinen T.A, Kononen J, Pelto-Huikko M et al. Expression of topoisomerase Iialpha is associated with rapid cell proliferation, aneuploidy, and c - erbB2 overexpression in breast cancer. Am J Pathol 1996; 148 (6): 2073-82.Kuerer H.M, Newman L.A, Smith T.L et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin - based neoadjuvant chemotherapy. J Clin Oncol 1999; 17 (2): 441-4.Lowe S.W, Ruley H.E, Jacks T et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.Ma X-J, Wang W, Salunga R et al. Gene expression signatures assotiated with clinical outcome in breast cancer via laser capture microdissection. Breast Cancer Res Treat 2003; 82: (abstract 29).Mac Grogan G, Rudolph P, Mascarel Id I et al. DNA topoisomerase IIalpha expression and the response to primary chemotherapy in breast cancer. Br J Cancer 2003; 89 (4): 666-71.Manders P, Beex L.V, Tjan-Heijen V.C et al. Vascular endothelial growth factor levels do not predict efficacy of systemic adjuvant treatment as assessed in 1127 breast cancer patients. Int J Oncol 2004; 25 (2): 511-7.Mc Laughlin R, O’Hanlon D, Mc Hale T et al. Prognostic implications of p53 and bcl-2 expression in 108 women with stage two breast cancer. Int J Med Sci 2001; 170 (1): 11-3.Muss H.B, Thor A.D, Berry D.A et al. c - erbB-2 overexpression and response to adjuvant therapy in women with node - positive early breast cancer. N Engl J Med 1994; 330: 1260-6.Paik S, Bryant J, Park C et al. erbB-2 and response to doxorubicin in patients with axillary lymph node - positive, hormone - receptor - negative breast cancer. J Natl Cancer Inst 1990; 90: 1361-70.Penault-Llorca F, Cayre A, Bouchet Mishellany F et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 2003; 22 (6): 1319-25.Perou C.M, Sorlie T, Elsen M.B et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-52.Petit T, Borel C, Ghnassia J.P et al. Chemotherapy response of breast cancer depends on Her-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 2001; 7: 1577-81.Petit T, Wilt M, Velten M et al. Comparative value of tumor grade, hormonal receptors, Ki-67, Her-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline - based chemotherapy. Eur J Cancer 2004; 40 (2): 205-11.Poelman S.M, Adeyanju M.O, Robertson M.A et al. Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res 2000; 6: 4043-8.Pusztai L, Ayers M, Simmans F.W et al. Emerging science: Prospective validation of gene expression profiling - based prediction of complete pathologic response to neoadjuvant paclitaxelFAC chemotherapy in breast cancer. Proc Am Soc Oncol 2003; 22: 1 (abstr. 1).Pusztai l, Krishnamurthy S, Perez-Cardona J et al. Expression of BAG-1 and BCL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. Cancer Invest 2004; in press.Ravdin P.M, Green S, Albain K.S et al. Initial report of the SWOG biological correlative study of C-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone (abstract). Proc Am Soc Clin Oncol 1998; 17 (astract 374).Ravdin P, Olivotto I.A, Speers C et al. Should estrogen receptor (ER) negativity alone be an indication for chemotherapy in T1N0 breast cancer? Proc Am Soc Clin Oncol 2003; 22: (abstract 55).Sataloff D.M, mason B.A, Prestipino A.J et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995; 180 (3): 297-306.Seidman A.D, Fornier M, Esteva F.J et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by Her2 immunophenotype and gene amplification. J Clin Oncol 2001; 19: 2587-95.Semiglazov V.F, Zhiltsova E.K, Bozhok A.A et al. Preoperative hormonal therapy vs chemotherapy in postmenopausal ER-positive breast cancer patients. Eur J Cancer 2004; 2: 71.Sjostrom J, Blomqvist C, Heikkila P et al. Predictive value of p53, mdm-2, p21 and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 2000; 6: 3103-10.Slamon D.J, Clark G.M, Wong S.G et al. Human breast cancer: correlation of relapse and survival with amplification of the Her-2neu oncogene. Science 1987; 235: 177-82.Sorlie T, Perou C.M, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74.Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-23.Stal O, Sullivan S, Wingren S et al. c - erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995; 31A: 2185-90.Sun J.M, Han W, Kim D.W et al. Clinical relevance of Her-2 expression in node - negative breast cancer patients. Proc Am Soc Clin Oncol 2004; 23: (abstract 598).Symmans W.F, Ayers M, Clark E.A et al. Total RNA yield and microarray gene expression profile from fine - needle aspiration biopsy and core - needle biopsy samples of breast carcinoma. Cancer 2003; 97: 2960-71.Tetu B, Brisson J. Prognostic sognoficance of Her-2neu oncoprotein expression in node - positive breast cancer: The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994; 73: 2359-65.Thor A.D, Berry D.A, Budman D.R et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node - positive breast cancer. J Natl Cancer Inst 1998; 90: 1346-60.Thorpe S.M, Rose C, Rasmussen B.B et al. Steroid hormone receptors as prognostic ondicators in primary breast cancer. Breast Cancer Res Treat 1986; 7: 91-8.Untch M, Kahlert S, Moebus V et al. Negative steroid receptors are a good predictor for response to preoperative chemotherapy in breast cancer (BC) - results of a randomized trial. Proc Am Soc Oncol 2003; 22: (abstract 35).Van Noef M.E, Knox W.F, Dhesi S.S et al. Assessment of tumor vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 1993; 29A: 1141-5.Van Poznak C, Tan L, Panageas K.S et al. Assesment of molecular markers of clinical sensivity to single - agent taxane therapy for metastatic breast cancer. J Clin Oncol 2002; 20: 2319-26.Van’t Veer L.J, Dai H, van de Vijver M.J et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6.Vincent-Salomon A, Rousseau A, Jouve M et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline - based preoperative chemotherapy. Eur J Cancer 2004; 40 (10): 1502-8.Wahl A.F, Donaldson K.L, Fairchild C et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2M arrest and apoptosis. Nat Med 1996; 2: 72-9.Weidner N, Semple J.P, Welch W.R et al. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.Zhang C.C, Yang J.M, Bash-Babula J et al. DNA damage increases sensivity to vinca alkaloids and decreases sensivity to taxanes through p53-dependent repression of microtubule - associated protein 4. Cancer Res 1999; 59: 3663-70.Zhu L, chow L.W, Loo W.T et al. Her2neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. Clin Cancer Res 2004; 10 (14): 4639-44.